Segmentation of the Flow Diverters Market
Device design choices define competition in the flow diverters market. Polaris Market Research valued the market at USD 386.23 million in 2025 and projects USD 1,110.14 million by 2034 at a CAGR of 12.45%. The report segments it by flow diverter type, application, material, delivery system, and region.
Pipeline Embolization Device Leads by Type
The pipeline embolization device (PED) segment held the largest share, 44.0%, in 2025. The PED is a self-expanding, stent-like device designed to redirect blood flow away from an aneurysm, and it is favored for treating large and wide-necked aneurysms that cannot be addressed through conventional methods. Its success rate and safety profile have driven its dominant position, particularly in North America and Europe.
The flow modulation device (FMD) segment is growing fastest among the types, at a CAGR of 14.84%, owing to increasing clinical adoption as a less invasive alternative to PED. Stent-assisted coiling (SAC) continues to be used in certain cases, using coils alongside stents, but it can be more invasive and is associated with higher complication rates. FMDs offer a similar treatment approach to PED, focusing on reducing the risk of device-related complications. Other emerging technologies remain limited in share.
By application, intracranial aneurysms account for 68.0% of the market, while arteriovenous malformations are the fastest-growing application at a 14.75% CAGR. Regionally, North America held 39.0% in 2025 and Europe 28.0%, while Asia Pacific is growing fastest at a 15.27% CAGR.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :
https://www.polarismarketresearch.com/industry-analysis/flow-diverters-market
Nitinol and Cobalt-Chromium Alloys
By material, the nitinol segment held the largest share, 56.0%, in 2025. Nitinol is a shape-memory alloy known for superior flexibility, biocompatibility, and ease of deployment, able to return to a pre-set shape when heated, and it conforms to vascular structures without causing damage, which suits challenging anatomical locations. Its widespread use in products like PED has solidified its position.
The cobalt-chromium alloy segment is growing fastest at a CAGR of 11.92%, driven by strength and radiopacity, which improve visibility during procedures. These alloys are useful where high radial force and resistance to fracture are needed. Stainless steel and other materials contribute less because of lower flexibility and a higher risk of complications in certain applications.
Catheter-Based Delivery System Versus Over-the-Wire
The catheter-based delivery system segment dominated with a 56.0% share in 2025, owing to ease of use and shorter procedure time. These systems are flexible, can be used in smaller or more tortuous vessels, and are associated with less trauma to vascular structures, which supports faster recovery.
The over-the-wire delivery system segment is expected to register a 10.60% CAGR. It is preferred for precision and control in complex vascular anatomies and has been widely used in clinical settings for over a decade.
Competitive Landscape and Key Players
Key players include Medtronic, Stryker Corporation, Johnson & Johnson (via its subsidiary, Neurovascular), Abbott Laboratories, Terumo Corporation, Boston Scientific, MicroVention (a subsidiary of Terumo), Sequent Medical (now part of Johnson & Johnson), and Penumbra, Inc., along with Asahi Intecc, Balt Extrusion, Cook Medical, Endospan, Neuroform, and EndoMed Systems. Competition is shaped by technological advancements, product differentiation, and expanding geographic presence. Medtronic's PED has been one of the market's most successful products, and Terumo's acquisition of MicroVention has strengthened its range of neurovascular products. Stryker has been expanding its neurovascular portfolio through strategic investments and acquisitions. Strategic partnerships, acquisitions, and collaborations with healthcare providers are common ways to strengthen market position and expand distribution networks, and companies must also navigate regulatory requirements to secure timely product approvals. The need for clinical evidence to support new product introductions remains a key area of competition.
Recent developments include Peijia Medical's March 2026 FDA 510(k) clearance of its DCwire Micro Guidewire, its first FDA-approved product, and Kaneka Medical America's January 2026 exclusive U.S. distribution partnership with Enlight Medical to bring neurovascular guidewire technology to the U.S. market.
Conclusion
The Flow Diverters Market is anticipated to experience sustained development due to increasing adoption of minimally invasive neurovascular procedures and advancements in aneurysm treatment technologies. Growing clinical interest in endovascular approaches is encouraging demand for sophisticated flow-diverting devices. Improvements in stent design, delivery systems, and imaging-guided procedures are supporting treatment precision and procedural efficiency. Additionally, ongoing clinical research is expanding understanding of patient selection, device performance, and long-term outcomes. However, high treatment costs, procedural risks, and specialized training requirements remain important market considerations. Overall, the market is expected to advance through device innovation, clinical evidence development, and increasing access to specialized neurovascular care.